SEC EDGARSEP 11 min read$ORKA

Sandler Laura Lee sold $459K of ORKA

Sandler Laura Lee (Chief Operating Officer) sold 5,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $91.82 ($91.05–$92.01, $0.46M total) across 2 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Sandler Laura Lee

Published Sep 1, 2026, 10:36 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 1, 2026, 11:27 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ORKA

Neutral

high confidence

Mentioned

$ORKA

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ORKANeutralLow

Why it matters

The sale represents a modest reduction in insider stake with limited market impact.

Market read

Routine insider sale; unlikely to move the stock significantly.

What to watch

Potential upcoming catalyst not disclosed; sale may be unrelated.

Relevance 3/10Novelty 2/10Timing: 2026‑09‑01 filing

Background

Form 4 filing discloses insider transactions; investors monitor for material changes.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ORKANeutralHigh confidence

Context

Chief Operating Officer sold 5,000 shares for $459K via a 10b5‑1 plan.

Expected impact

Minimal effect on stock price.

Evidence & confidence

Sale size is small relative to float and disclosed via Form 4, typical for insiders.

Market effects

Sector

No broader sector impact; biotech insider sales are routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

If the insider is cashing out due to concerns, could signal downside.

Key entities

Company
Oruka Therapeutics, Inc.
Biotech firm listed on NASDAQ under ORKA.
Insider
Laura Lee Sandler
Chief Operating Officer of Oruka Therapeutics.

Read at source ← All news

AUG 11

$ORKAMed

Oruka Q2 Net Loss Expands; Expects Phase 2 EVERLAST-A 28 Week Data Of ORKA-001 At The End Of Q3 2026

Oruka Therapeutics (ORKA) reported Q2 2026 net loss of $41.21 million, up from $24.57 million a year earlier. The company said it had $1.1 billion in cash, cash equivalents and marketable securities as of June 30, 2026. Phase 2 EVERLAST-A 28-week data for ORKA-001 is expected end of Q3 2026, with 52-week data in Dec 2026.

rttnews.com3 min

AUG 10

$ORKAMedAI 8/10

Oruka Therapeutics reports Q2 2026 results: $1.1B cash; net loss $41.2M in quarter

Oruka Therapeutics reported Q2 2026 cash, cash equivalents and marketable securities of $1.1B as of June 30, 2026, and a net loss of $41.2M. R&D was $43.3M and G&A $6.9M, with $8.9M interest income. The company cited clinical updates for ORKA-001 and ORKA-002 and said funding should support a BLA filing for ORKA-001.

tradingview.com1 min

AUG 10

$ORKAMed

Oruka Therapeutics, Inc. (ORKA): Results of Operations and Financial Condition

Oruka Therapeutics, Inc. (ORKA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 1

SEC EDGAR 8-K6 min

JUL 2

$ABBVMed

Biotech Gives SBIO Its Best Month Since 2023

In June, the ALPS Medical Breakthroughs ETF (SBIO) returned 18.7%, its best month since Dec 2023, according to VettaFi. Apogee Therapeutics (APGE) added 2.18 pts after AbbVie (ABBV) agreed to acquire it for about $10.9B ($135.11/share). Definium (DFTX) added 1.58 pts after a Phase 3 MDD readout; other movers included Oruka (ORKA).

etftrends.com4 min

JUL 2

$ORKALowAI 9/10

Fairmount Funds Management LLC sold $300.0M of ORKA (indirect holdings)

Fairmount Funds Management LLC sold 3,553,410 indirectly-held shares of Oruka Therapeutics, Inc. (ORKA) at $84.43 ($300.01M total) on 2026-07-01.

SEC EDGAR1 min

MAY 31

$ORKALow

An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million

According to an SEC Form 4 filed May 21, 2026, Oruka Therapeutics director Carl Dambkowski sold 105,000 shares of common stock for about $6.19 million at a weighted average price of $58.97. After the sale, he held 73,743 shares (~$4.33 million). The shares came from exercising 62,260 vested options.

finance.yahoo.com4 min